For a patient who cannot swallow a tablet, a cholesterol pill is not much use, and that gap is the reason a liquid statin exists at all. Now the U.S. Food and Drug Administration has moved to take that option off the market, and the reason has nothing to do with whether the medicine works.
The agency has proposed withdrawing approval of FloLipid, a simvastatin oral suspension sold in 20 mg/5 mL and 40 mg/5 mL strengths, after its maker, Salerno Pharmaceuticals of Tulsa, Oklahoma, repeatedly failed to file required annual reports. The proposal is not final, and the company still has a window to answer.
What the Federal Register notice says
The proposal appears in a notice from the agency’s Center for Drug Evaluation and Research, signed by center director Michael Davis, that was filed for public inspection on Nov. 17 and scheduled for publication on Nov. 18. It concerns application NDA 206679 under docket FDA-2026-N-9703. The notice states that “Salerno Pharmaceuticals has repeatedly failed to submit the required annual reports,” and adds that the company did not respond when the agency asked for them.
A proposal to withdraw is the opening step, not the closing one. The notice says that if no hearing is requested and no case is made, the FDA “will then withdraw approval of the NDA.” Until that happens, the approval remains on the books. What a final withdrawal would mean in practice is spelled out by Cardiovascular Business: if Salerno does not request a hearing in time, it waives its contentions about the drug’s legal status, the FDA withdraws the approval, and the products could no longer be lawfully shipped across state lines. The outlet adds that the liquid, which was designed for patients with trouble swallowing pills, does not require refrigeration, and that the proposal covers both the 20 mg and 40 mg doses. It also dates the formulation’s first FDA approval to 2016.
The paperwork at the center of the dispute
Annual reports are a standing duty for every holder of an approved new drug application. Under 21 CFR 314.81, the report is due within 60 days of the anniversary of U.S. approval and must be accompanied by Form FDA 2252. It must summarize significant new safety or effectiveness information from the past year, report how many dosage units were distributed by strength, include current labeling, and flag any changes to manufacturing and controls.
In other words, the filing is how the agency learns whether a product is still being made, sold and monitored. A company that goes silent leaves the FDA with no way to confirm any of it.
Nothing in the notice, as described by Fierce Pharma, alleges a safety or efficacy problem with simvastatin itself. The trade outlet reported that Salerno did not immediately respond to a request for comment, that its website lists no traditional press releases and only two board members, and that FloLipid was the only product listed under the company’s name on a September FDA list of approved medicines.
Deadlines for Salerno
The company has until Dec. 18 to request a hearing, according to Fierce Pharma. If it does, it then has until Jan. 19, 2027, to submit data, analyses and written comments. The notice also warns that a hearing request “may not rest upon mere allegations or denials,” meaning the company would need to bring actual evidence to contest the proposal.
Whether Salerno responds at all is the open question, and neither trade report quotes anyone from the company. A firm that skipped its annual filings and ignored the agency’s request for them has shown little sign of engaging, but nothing in the public record yet shows what it will do.
A liquid option with a short history
FloLipid is marketed as the first liquid medicine approved in the United States to lower cholesterol, aimed at people who have difficulty swallowing pills, according to Fierce Pharma. Simvastatin itself dates to Merck’s Zocor, which was approved in the 1990s and passed to Organon in its 2021 spinout.
The product’s regulatory file goes back several years, and the paper trail shows the application changing hands along the way. An FDA letter dated Sept. 25, 2020 approved a labeling supplement for NDA 206679 that added a warning about immune-mediated necrotizing myopathy, a muscle condition the agency had identified across the statin class in a June 12, 2020 letter. At that time the application was held by TCG Fluent Pharma Investors LP of Brooksville, Florida, rather than Salerno.
The sources reviewed do not say how many people currently take FloLipid or whether another liquid simvastatin is approved. Patients on the product who are worried about supply should raise it with a prescriber or pharmacist; the notice itself does not order anyone to stop taking the drug. The next datable event is Dec. 18, when Salerno’s window to request a hearing closes.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- Over 20 trillion gallons of rain fell on the Four Corners states and Nevada in two weeks
- 11 engines built to run well past 200,000 miles
- Two Kentucky residents died when a small plane crashed at Missouri’s Lake of the Ozarks, and the NTSB is investigating
- A handful of car transmissions are so tough that mechanics say they almost never die